The DOI matches its Crossref record; 353 of the 372 references it cites were found in a registry or an index; 83 of the 236 sources its claims cite were checked for support.
Current State of Therapeutics for HTLV-1
Open accessAbstract
Human T cell leukaemia virus type-1 (HTLV-1) is an oncogenic retrovirus that causes lifelong infection in ~5–10 million individuals globally. It is endemic to certain First Nations populations of Northern and Central Australia, Japan, South and Central America, Africa, and the Caribbean region. HTLV-1 preferentially infects CD4+ T cells and remains in a state of reduced transcription, often being asymptomatic in the beginning of infection, with symptoms developing later in life. HTLV-1 infection is implicated in the development of adult T cell leukaemia/lymphoma (ATL) and HTLV-1-associated myelopathies (HAM), amongst other immune-related disorders. With no preventive or curative interventions, infected individuals have limited treatment options, most of which manage symptoms. The clinical burden and lack of treatment options directs the need for alternative treatment strategies for HTLV-1 infection. Recent advances have been made in the development of RNA-based antiviral therapeutics for Human Immunodeficiency Virus Type-1 (HIV-1), an analogous retrovirus that shares modes of transmission with HTLV-1. This review highlights past and ongoing efforts in the development of HTLV-1 therapeutics and vaccines, with a focus on the potential for gene therapy as a new treatment modality in light of its successes in HIV-1, as well as animal models that may help the advancement of novel antiviral and anticancer interventions.
Overview
CoChat Summary
## TL;DR
This review argues that HTLV-1 still lacks approved curative or preventive therapy, and that current treatment is largely symptomatic or repurposed from HIV and oncology drugs. It highlights gene-targeting approaches, especially RNAi and gene editing, plus BLV vaccination as the most promising directions for future HTLV-1 interventions.
## Key findings
- HTLV-1 causes lifelong infection in an estimated ~5–10 million people globally, with global prevalence estimates ranging from 3 to 30 million cases.
- The lifetime risk of ATL in carriers is estimated at 1–5%, and the risk of HAM at about 3%; among carriers, the risk of early neurological disorders can be as high as 24%.
- Existing ART has limited impact because it cannot eliminate HTLV-1 reservoirs driven by clonal expansion; for example, AZT + lamivudine in a randomized double-blind placebo-controlled HAM trial produced no significant reduction in PVL or clinical measures after 24 weeks.
- In HAM, a multicentre randomized phase III mogamulizumab study found no significant difference in the primary or secondary motor endpoints at the end of the double-blind period, but it did significantly reduce PVL and CSF CXCL10/neopterin; earlier phase I/IIa data in 21 patients reported improved motor ability in 32% and reduced spasticity in 79%.
- The BLV vaccine is presented as a model for HTLV-1 vaccination: in Argentina it conferred immunity in 28 of 29 cows over 4 years and was reported as safe and effective.
## Methods
- Narrative review of past and ongoing HTLV-1 therapeutics and vaccines, with emphasis on similarities to HIV-1 and on gene therapy/RNA-based approaches.
- Synthesizes evidence from cell models, animal models (mice, rabbits, non-human primates, humanized mice), and clinical studies/trials in ATL and HAM.
- Main analysis is comparative and descriptive, evaluating how different therapeutic strategies affect PVL, viral gene expression, tumor burden, and clinical outcomes.
## Limitations
- The paper states that there are no preventive or curative interventions for HTLV-1 and that there are no approved HTLV-1-specific inhibitors or antiviral ASOs.
- For HAM and other HTLV-1-associated inflammatory diseases, the paper notes that studies are often observational, with small cohorts and geographic constraints.
- Evident from the text: much of the evidence comes from preclinical models, and the review itself notes major gaps in in vivo/in vitro HTLV-1 studies, efficient delivery for gene therapies, and clinical translation of RNAi/gene-editing approaches.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
63 Valid · 10 Not valid · 85 Not checked · 51 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“HTLV-1 is primarily associated with the aggressive haematological malignancy ATL [1,2] and a chronic inflammatory disease called HTLV-1-associated myelopathies (HAM).”
§ Current State of Therapeutics for HTLV-1 > 1. Introduction > 1.5. HTLV-1-Associated Diseases
What the sources say
- Partly supportedcites [1] Poiesz, 1980, Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma, Proc. Natl. Acad. Sci. USA sourceExperimental — accuracy not yet measured
The paper reports HTLV particles in lymphocytes from a patient with cutaneous T-cell lymphoma (mycosis fungoides), supporting an association with a T-cell malignancy. It does not establish the more specific claim that HTLV-1 is primarily associated with ATL. The citation in the printed sentence is attached to ATL, not HAM. (LLM, conf=0.78)
- Not checked yetcites [2] Hinuma, 1981, Adult T-cell leukemia: Antigen in an ATL cell line and detection of antibodies to the antigen in human sera, Proc. Natl. Acad. Sci. USA source
Checked before — its earlier verdict is held back until a new check runs.
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“An ongoing issue of HTLV-1-infected cell lines is the underrepresentation of more divergent subtypes, with recent studies suggesting that different HTLV-1 subtypes exert significantly different influences over the host immune system compared to the dominant cosmopolitan subtype [19].”
§ Current State of Therapeutics for HTLV-1 > 2. In Vivo Assessment of Therapeutics > 2.1. Cell Models
What the sources say
- Partly supportedcites [19] Afonso, 2019, Molecular epidemiology, genetic variability and evolution of HTLV-1 with special emphasis on African genotypes, Retrovirology sourceExperimental — accuracy not yet measured
In “The genetic organization differs according to molecular genotypes” (page not provided), the review says HTLV-1b and HTLV-1c lack some accessory genes present in HTLV-1a and that one HTLV-1a accessory protein facilitates immune escape. It does not establish that different subtypes exert significantly different effects on the host immune system; it presents the implications of those genetic differences as hypotheses. (LLM, conf=0.83)
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“with previous studies suggesting a distinct pathogenesis [96,118,119,120].”
§ Current State of Therapeutics for HTLV-1 > 2. In Vivo Assessment of Therapeutics > 2.1. Cell Models
What the sources say
- Not checked — no full text of the sourcecites [96] Einsiedel, 2012, Bronchiectasis is associated with human T-lymphotropic virus 1 infection in an Indigenous Australian population, Clin. Infect. Dis. source
- Could not verifycites [118] Talukder, M.R., Pham, H., Woodman, R., Wilson, K., Taylor, K., Kaldor, J., and Einsiedel, L. (2022). The Association between Diabetes and Human T-Cell Leukaemia Virus Type-1 (HTLV-1) with Strongyloides stercoralis: Results of a Community-Based, Cross-Sectional Survey in Central Australia. Int. J. Environ. Res. Public Health, 19. sourceExperimental — accuracy not yet measured
The Introduction describes immune effects of HTLV-1 infection in people with Strongyloides, and Methods §2.5 mentions HTLV-1c only to identify the sequence targeted by a test. Neither passage says HTLV-1c has a distinct pathogenesis. Searches for “pathogenesis” and subtype-specific differences found no passage addressing that claim. (LLM, conf=0.74)
- Not checked — no full text of the sourcecites [119] Talukder, 2021, Risk factors for HTLV-1, acute kidney injury, and urinary tract infection among aboriginal adults with end stage kidney disease in central Australia, J. Med. Virol. source
- Not checked — no full text of the sourcecites [120] Talukder, 2023, High Human T-Cell Leukemia Virus Type 1c Proviral Loads Are Associated With Diabetes and Chronic Kidney Disease: Results of a Cross-Sectional Community Survey in Central Australia, Clin. Infect. Dis. source
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Overexpression of Hbz was observed to prevent Tax-induced NF-κB and PRC2 activation, shedding light on the co-modulatory interplay of Tax and Hbz [157].”
§ Current State of Therapeutics for HTLV-1 > 2. In Vivo Assessment of Therapeutics > 2.2. Animal Models
What the sources say
- Supportedcites [157] Akkouche, A., Moodad, S., Hleihel, R., Skayneh, H., Chambeyron, S., El Hajj, H., and Bazarbachi, A. (2021). In vivo antagonistic role of the Human T-Cell Leukemia Virus Type 1 regulatory proteins Tax and HBZ. PLoS Pathog., 17. source
The Results section reports that flies overexpressing both HBZ and Tax had significantly attenuated Tax-mediated NF-κB and PRC2 activation compared with flies expressing Tax alone; its Fig. 3 caption describes this as abrogation. A separate Results section reports that HBZ overexpression blocked Tax-induced PRC2 activation in human cells. Page numbers were not available in our copy. (LLM, conf=0.93)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The cessation of therapy in HIV is associated with a strong viral rebound to pre-therapeutic plasma viral loads [164,165,166]”
§ Current State of Therapeutics for HTLV-1 > 3. Current Treatments > 3.1. Antiretroviral Therapies and Limitations for HTLV-1
What the sources say
- Supportedcites [164] Hamlyn, E., Ewings, F.M., Porter, K., Cooper, D.A., Tambussi, G., Schechter, M., Pedersen, C., Okulicz, J.F., McClure, M., and Babiker, A. (2012). Plasma HIV viral rebound following protocol-indicated cessation of ART commenced in primary and chronic HIV infection. PLoS ONE, 7. source
The Introduction states that plasma viral load after ART cessation can reach levels comparable to pre-treatment values. The Discussion also reports that participants who began ART during primary HIV infection reached pre-ART viral-load levels after a median of 50 weeks. (LLM, conf=0.92)
- Partly supportedcites [165] Chun, 2010, Rebound of plasma viremia following cessation of antiretroviral therapy despite profoundly low levels of HIV reservoir: Implications for eradication, AIDS sourceExperimental — accuracy not yet measured
The Results report that plasma viremia rebounded after ART was stopped in one participant, reaching 1,593 and later 8,684 HIV RNA copies/ml. The Discussion says rebound is likely for the vast majority of people receiving ART. Neither passage establishes that viral loads returned to pre-therapy levels; the reported rebound was also delayed by 50 days in the participant studied. (LLM, conf=0.86)
- Not checked — no full text of the sourcecites [166] Colven, 2000, Retroviral rebound syndrome after cessation of suppressive antiretroviral therapy in three patients with chronic HIV infection, Ann. Intern. Med. source
boostedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
60 more claims · 17 with their cited sources checked
Create a free account to see all 209 claims and to verify the 41 references still open.
- It may state two separate claims as one. 103
- Probably not a substantial claim. 64
- The quote only partly states this claim. 2
Citations
Cites
CRISPR Provides Acquired Resistance Against Viruses in Prokaryotes
Barrangou, R., Fremaux, C., Deveau, H., Richards, M., Boyaval, P., Moineau, S., Romero, D. A., & Horvath, P. (2007) · Science · doi:10.1126/science.1138140 · Cited by 5,947 · cited 1×
“As has an exceptionally conserved genome, it is a HTLV-1 has an exceptionally conserved genome, it is a promising candidate for the sequence-specific and highly potent RNAi. promising candidate for the sequence-spe-ci fi c and highly potent RNAi.”
BackgroundPoiesz, B. J., Ruscetti, F. W., Gazdar, A. F., Bunn, P. A., Minna, J. D., & Gallo, R. C. (1980) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.77.12.7415 · Cited by 5,043 · cited 2×
“Multiple animal models are available, including mice, rats, rabbits, and non-human primates (NHPs).”
BackgroundHigh-Frequency off-Target Mutagenesis Induced by CRISPR-Cas Nucleases in Human Cells
Fu, Y., Foden, J. A., Khayter, C., Maeder, M. L., Reyon, D., Joung, J. K., & Sander, J. D. (2013) · Nature Biotechnology · doi:10.1038/nbt.2623 · Cited by 3,292 · cited 1×
“…hairpin RNA; RISC, RNA-induced silencing complex; RITS, RNA-induced transcriptional silencing complex; TRBP, transactivating response (TAR) RNA-binding protein; TNRC6, trinucleotide repeat containing 6 protein faily. mediated by the RITS complex, acting through repressive epigenetic modifications.”
BackgroundEvidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles
Davis, M. E., Zuckerman, J. E., Choi, C. H. J., Seligson, D., Tolcher, A., Alabi, C. A., Yen, Y., Heidel, J. D., & Ribas, A. (2010) · Nature · doi:10.1038/nature08956 · Cited by 2,505
Hinuma, Y., Nagata, K., Hanaoka, M., Nakai, M., Matsumoto, T., Kinoshita, K. I., Shirakawa, S., & Miyoshi, I. (1981) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.78.10.6476 · Cited by 2,252
A severe combined immunodeficiency mutation in the mouse
Bosma, G. C., Custer, R. P., & Bosma, M. J. (1983) · Nature · doi:10.1038/301527a0 · Cited by 2,207 · cited 1×
“Other NHPs susceptible to HTLV-1 infection include squirrel monkeys, cynomolgus monkeys, and rhesus macaques.”
BackgroundYoshida, M., Miyoshi, I., & Hinuma, Y. (1982) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.79.6.2031 · Cited by 2,169 · cited 2×
“Over the past three decades, a variety of animal models have been developed to help elucidate the events of HTLV-1 pathogenesis and evaluate novel therapeutics.”
BackgroundViral RNA-dependent DNA Polymerase: RNA-dependent DNA Polymerase in Virions of Rous Sarcoma Virus
TEMIN, H. M., & MIZUTANI, S. (1970) · Nature · doi:10.1038/2261211a0 · Cited by 2,128
Finzi, D., Blankson, J., Siliciano, J. D., Margolick, J. B., Chadwick, K., Pierson, T., Smith, K., Lisziewicz, J., Lori, F., Flexner, C., et al. (1999) · Nature Medicine · doi:10.1038/8394 · Cited by 2,119 · cited 1×
“…in endemic areas who present with associated diseases such as Sjogren’s syndrome, thyroiditis, pulmonary disease, and opportunistic infections will bene fi t from anti-HTLV-1 antibody testing, and screening should be recommended in clinics for sexually transmi tt ed infections. disease development.”
BackgroundViral RNA-dependent DNA Polymerase: RNA-dependent DNA Polymerase in Virions of RNA Tumour Viruses
BALTIMORE, D. (1970) · Nature · doi:10.1038/2261209a0 · Cited by 2,068 · cited 1×
“Detected in 1980 [1,2] through the isolation of T-lymphoblastoid cell lines, human T cell leukaemia virus type-1 (HTLV-1) became the first discovered oncogenic retrovirus, following the characterisation of reverse transcriptase in 1970 [3,4].”
BackgroundInfluential
Research works printed but not linked: 2
- Ribas, 2002, Infection and disease caused by the human T cell lymphotropic viruses type I and II in Brazil, Rev. Soc. Bras. Med. Trop., 35, 499
- Cruz, 2012, Chronic rhinitis in HTLV-1 carriers: A histopathologic study, Braz. J. Otorhinolaryngol., 78, 35
Cited by
Viral oncogenesis in cancer: from mechanisms to therapeutics
Xiao, Q., Liu, Y., Li, T., Wang, C., He, S., Zhai, L., Yang, Z., Zhang, X., Wu, Y., & Liu, Y. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02197-9 · Cited by 128
Human T-Lymphotropic Virus (HTLV): Epidemiology, Genetic, Pathogenesis, and Future Challenges
Branda, F., Romano, C., Pavia, G., Bilotta, V., Locci, C., Azzena, I., Deplano, I., Pascale, N., Perra, M. T., Giovanetti, M., et al. (2025) · Viruses · doi:10.3390/v17050664 · Cited by 47
“Currently, treatment options for HTLV-1 are limited and focus primarily on symptom management, with few curative interventions available [171].”
Combination antiretroviral therapy and MCL-1 inhibition mitigate HTLV-1 infection in vivo
Cooney, J. P., Hirons, A., Jansz, N., Allison, C. C., Hickey, P. F., Teh, C. E., Tan, T., Dagley, L. F., Yousef, J. M., Yurick, D., et al. (2025) · Cell · doi:10.1016/j.cell.2025.06.023 · Cited by 18
Self-citationOncoviruses in the Oral Cavity: Recent Advances in Understanding Viral Infections and Tumorigenesis
Campos, L., Guimarães, A. C. S., Pereira, J. G., da Silva, C. S., de Almeida, N. A. A., Marinho, P. D. N., de Sousa, R. M. P., Duś‐Ilnicka, I., & de Paula, V. S. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26146721 · Cited by 10
“Therefore, this vaccine may provide a model against HTLV-1 that requires the stimulation of humoral and cytotoxic immune responses [274,278].”
Mikame, Y., Toyama, H., Dohno, C., Wada, T., & Yamayoshi, A. (2025) · Communications Chemistry · doi:10.1038/s42004-025-01416-2 · Cited by 5
Metadata
- Authors
- Wang, T. T., Hirons, A., Doerflinger, M., Morris, K. V., Ledger, S., Purcell, D. F. J., Kelleher, A. D., & Ahlenstiel, C. L.
- Affiliations
- UNSW Sydney (AU)
- The University of Melbourne (AU)
- Queensland University of Technology (AU)
- Corresponding author
- Ahlenstiel, Chantelle L.
- ORCID
- Venue
- Viruses
- Publisher
- MDPI AG
- Published
- 2024-10-15
- Volume
- 16
- Issue
- 10
- Pages
- 1616
- ISSN
- 1999-4915 (ISSN-L)
- PMC
- PMC11512412
- OpenAlex
- W4403429851
- Cited by
- 22
- References
- 372
- Citations by year
- 2026: 9 · 2025: 12 · 2024: 1
- FWCI
- 0.97
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Viruses (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Minerva Access (University of Melbourne) (submittedVersion, cc-by)
- Funders
- an Australian Government Research Training Program Scholarship (APP1149990, GNT2004670, R01 1R01MH134389-01 NIMH)
- an NHMRC programme grant (APP1149990, GNT2004670, R01 1R01MH134389-01 NIMH)
- a UNSW Rapid Response Research grant (APP1149990, GNT2004670, R01 1R01MH134389-01 NIMH)
- the NSW RNA Production Research Network (APP1149990, GNT2004670, R01 1R01MH134389-01 NIMH)
- a philanthropic grant to the Immunotherapy Research Fund at the Kirby Institute (APP1149990, GNT2004670, R01 1R01MH134389-01 NIMH)
- the Australian NHMRC Ideas grant (APP1149990, GNT2004670, R01 1R01MH134389-01 NIMH)
- Australian Centre for HIV and Hepatitis Virology Research (ACH4) Project Grants (APP1149990, GNT2004670, R01 1R01MH134389-01 NIMH)
- the ACH4 and the Phyllis Connor Memorial Trust (APP1149990, GNT2004670, R01 1R01MH134389-01 NIMH)
- NIH (APP1149990, GNT2004670, R01 1R01MH134389-01 NIMH)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and Retrovirus Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
- Keywords
- HTLV-1, antiviral agents, gene therapy, adult T-cell leukemia/lymphoma, tropical spastic paraparesis, retroviral infection, CD4+ T cells, HIV-1, vaccine development, animal models, oncogenic retroviruses
- MeSH terms
- Animals, Antiviral Agents, Humans, Viral Vaccines, Human T-lymphotropic virus 1, Leukemia-Lymphoma, Adult T-Cell, HTLV-I Infections
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Current State of Therapeutics for HTLV-1. https://app.cochat.ai/papers/10.3390/v16101616
- The paper
- Wang, T. T., Hirons, A., Doerflinger, M., Morris, K. V., Ledger, S., Purcell, D. F. J., Kelleher, A. D., & Ahlenstiel, C. L. (2024). Current State of Therapeutics for HTLV-1. Viruses. https://doi.org/10.3390/v16101616
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.